Revised forecast
Fiscal year ending March 2026 · Full yearPrevious forecast published 28 April 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The slower pace of recovery in net sales, particularly in the Career Business and overseas business; investments made to support medium- to long-term growth; and the recognition of an impairment loss of ¥22,957 million as an extraordinary loss.
Consolidated impairment loss of ¥22,957 million, comprising ¥13,041 million in trademarks, ¥8,649 million in goodwill, ¥677 million in software and ¥589 million in customer-related assets. The company also recognized an impairment loss of ¥29,667 million on shares of affiliates in the non-consolidated financial statements, but this had no impact on consolidated profit or loss.
| Item | Details |
|---|---|
| Net Sales | 67,544 Millions of yen → 64,735 Millions of yen（-4.2%） |
| Operating profit | 7,287 Millions of yen → 6,787 Millions of yen（-6.9%） |
| Ordinary income | 9,468 Millions of yen → 8,721 Millions of yen（-7.9%） |
| Profit attributable to owners of the parent | 7,029 Millions of yen → -14,317 Millions of yen |
| Net income per share | 82.39 yen → -173.66 yen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 28 April 2025 |
| Previous-period results | Net sales: ¥60,952 million; operating income: ¥6,335 million; ordinary income: ¥8,357 million; net income attributable to owners of the parent: ¥6,054 million; basic earnings per share: ¥70.96 (fiscal year ended March 2025) |
| Reason for the revision | The slower pace of recovery in net sales, particularly in the Career Business and overseas business; investments made to support medium- to long-term growth; and the recognition of an impairment loss of ¥22,957 million as an extraordinary loss. |
| Details and amount of extraordinary loss | Consolidated impairment loss of ¥22,957 million, comprising ¥13,041 million in trademarks, ¥8,649 million in goodwill, ¥677 million in software and ¥589 million in customer-related assets. The company also recognized an impairment loss of ¥29,667 million on shares of affiliates in the non-consolidated financial statements, but this had no impact on consolidated profit or loss. |
| Dividend forecast revision | No change. The dividend forecast for the fiscal year ending March 2026 remains ¥29.5 per share. |
| Consolidated / non-consolidated | Consolidated |
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In addition to the delayed recovery in net sales, particularly in the Career Business and overseas business, the company made investments aimed at medium- to long-term growth, causing net sales and profit at each stage to fall below the initial plan. The recognition of an impairment loss of ¥22,957 million on the overseas business as an extraordinary loss also resulted in a substantial decline in net income attributable to owners of the parent. The company also cited the prolonged budget restraints resulting from the expiration of patents on key drugs of major pharmaceutical companies and other factors, as well as a review of future plans in response to the worsening situation in the Middle East.